Views of adults with cystic fibrosis on switching their current treatment
Asks adults with cystic fibrosis how they feel about switching to vanzacaftor/tezacaftor/deutivacaftor.
Plain-language title generated from the registry record
Registry title: PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in Treatment
Key facts
- Where
- Caen, Giens, Grenoble, Lille, Lyon, Montpellier, Paris, Reims, Rennes, Roscoff, Rouen, and Vannes, FranceSee the 12 sites
Where in France
- CRCM CaenCaen, FranceNot yet recruiting
- CRCM GiensGiens, FranceTaking people
- CRCM GrenobleGrenoble, FranceTaking people
- CRCM LilleLille, FranceNot yet recruiting
- CRCM LyonLyon, FranceNot yet recruiting
- CRCM MontpellierMontpellier, FranceTaking people
- CRCM ParisParis, FranceNot yet recruiting
- CRCM ReimsReims, FranceTaking people
- CRCM Rennes adultesRennes, FranceNot yet recruiting
- Fondation ILDYSRoscoff, FranceTaking people
- CRCM RouenRouen, FranceTaking people
- CRCM VannesVannes, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fondation Ildys
- Trial code
- NCT07885410
- Record updated
- 28 October 2026
- Original description
PERCE-MUCO is a prospective, multicentre, mixed-methods observational study investigating the perceptions, expectations and treatment-change intentions of adults with cystic fibrosis who are currently treated with elexacaftor/tezacaftor/ivacaftor (ETI) or whose treatment has been medically discontinued. The study focuses on patients' stated willingness to switch from ETI to vanzacaftor/tezacaftor/deutivacaftor (VTD), and on the factors associated with this intention, including treatment satisfaction, knowledge and expectations regarding VTD, quality of life, treatment adherence, reported adverse effects, access-related concerns and desired support from an advanced practice nurse. The quantitative component uses a study-specific questionnaire and routine-care CFQ-R 14+ and Morisky-8 data. A qualitative component consists of semi-structured interviews at the Roscoff cystic fibrosis centre.Read full original descriptionShow less
Perceptions and Expectations of Patients Regarding a Change in Treatment in Cystic Fibrosis (PERCE-MUCO)
PERCE-MUCO is a prospective, multicentre, mixed-methods observational study investigating the perceptions, expectations and treatment-change intentions of adults with cystic fibrosis who are currently treated with elexacaftor/tezacaftor/ivacaftor (ETI) or whose treatment has been medically discontinued. The study focuses on patients' stated willingness to switch from ETI to vanzacaftor/tezacaftor/deutivacaftor (VTD), and on the factors associated with this intention, including treatment satisfaction, knowledge and expectations regarding VTD, quality of life, treatment adherence, reported adverse effects, access-related concerns and desired support from an advanced practice nurse. The quantitative component uses a study-specific questionnaire and routine-care CFQ-R 14+ and Morisky-8 data. A qualitative component consists of semi-structured interviews at the Roscoff cystic fibrosis centre.
Inclusion: Diagnosis of cystic fibrosis; Currently treated with ETI for at least 3 months, OR previously treated with ETI but treatment discontinued for medical reasons.
Exclusion: Currently receiving the new CFTR modulator VTD; Patient objects to the use of their data for this project\n•.